

# Spurious Elevations of Vitamin B<sub>12</sub> with Pernicious Anemia

**TO THE EDITOR:** Within a 3-week period, two women, 46 and 48 years of age, presented with peripheral neuropathy and associated pancytopenia with macrocytic anemia. Clinical suspicion for pernicious anemia was high, but vitamin B<sub>12</sub> levels were 1644 pg per milliliter (1228 pmol per liter) and 1321 pg per milliliter (975 pmol per liter), respectively (reference range, 246 to 1320 pg per milliliter [181 to 974 pmol per liter]). On subse-


quent bone-marrow evaluation, specimens from both patients showed profound megaloblastic features. Additional findings on laboratory tests included elevated levels of homocysteine and methylmalonic acid combined with detection of intrinsic factor–blocking antibodies and anti-parietal-cell antibodies, which further supported the diagnosis of pernicious anemia. In both patients the blood counts responded to treatment

with vitamin B<sub>12</sub>, but both continue to have symptoms of peripheral neuropathy.

There have been reports of false normal results for vitamin B<sub>12</sub> levels generated by automated analyzers when the serum of patients with megaloblastic anemia is evaluated. The results have been attributed to the possibility that high levels of intrinsic factor–blocking antibodies interfere with the assay.<sup>1,2</sup> Today, vitamin B<sub>12</sub> assays are primarily performed on automated analyzers that apply a method based on the competitive binding of serum vitamin B<sub>12</sub> with reagent intrinsic factor. Many of these platforms have also been found to be inaccurate when serum containing intrinsic factor–blocking antibodies is analyzed.<sup>2</sup> Disconcertingly, pernicious anemia is the most common cause of vitamin B<sub>12</sub> deficiency, and up to 70% of patients with pernicious anemia have intrinsic factor–blocking antibodies.<sup>3</sup>

To investigate further, we precipitated serum immunoglobulins by adding 25% polyethylene glycol (PEG) by volume in a 1:1 dilution with serum. Using unmodified and PEG-treated samples of serum from the two patients and from three controls (patients without macrocytic anemia), we then ran tests for vitamin B<sub>12</sub> levels (Fig. 1). In the PEG-treated samples from the two patients, vitamin B<sub>12</sub> levels decreased to below the limit of detection; the PEG-treated samples from the controls showed a decrease compatible with the 1:1 dilution.

We have been performing vitamin B<sub>12</sub> assays on the Siemens Dimension Vista system at our institution. A review of the package insert shows that the manufacturers are aware of this issue and recommend testing for intrinsic factor–blocking antibodies if test results are in conflict with the clinical diagnosis. We are in the midst of evaluating other platforms for this assay and have notified our clinicians of the issues described. However, we are concerned that there is insufficient awareness in the medical community of the possibility of spuriously high vitamin



**Figure 1. Spuriously Elevated Vitamin B<sub>12</sub> Levels in Two Patients with Pernicious Anemia.**

Vitamin B<sub>12</sub> levels in serum samples to which polyethylene glycol (PEG) had been added and serum samples to which PEG had not been added are shown for two patients with pernicious anemia and three controls without anemia who had normocytic red cells. To convert the values for vitamin B<sub>12</sub> to picomoles per liter, multiply by 0.7378.

B<sub>12</sub> levels; we urge pathologists to review their methods and clinicians to incorporate the information presented here into their diagnostic evaluations.

David T. Yang, M.D.  
Rachel J. Cook, M.D.

University of Wisconsin School of Medicine and Public Health  
Madison, WI  
dtyang@wisc.edu

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

1. Vlasveld LT, van't Wout JW, Meeuwissen P, Castel A. High measured cobalamin (vitamin B<sub>12</sub>) concentration attributable to an analytical problem in testing serum from a patient with pernicious anemia. *Clin Chem* 2006;52:157-9. [Erratum, *Clin Chem* 2006;52:342.]
2. Hamilton MS, Blackmore S, Lee A. Possible cause of false normal B-12 assays. *BMJ* 2006;333:654-5.
3. Toh BH, van Driel IR, Gleeson PA. Pernicious anemia. *N Engl J Med* 1997;337:1441-8.